Application of a hemophilia mortality framework to the Emicizumab Global Safety Database-Reference-Cited by-同舟云学术

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Published:2020-12-16 Issue:S1 Volume:19 Page:32-41
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Peyvandi Flora¹²^ORCID,Mahlangu Johnny N.³,Pipe Steven W.⁴^ORCID,Hay Charles R. M.⁵,Pierce Glenn F.⁶,Kuebler Peter⁷,Kruse‐Jarres Rebecca⁸⁹,Shima Midori¹⁰

Affiliation:

1. IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan Italy

2. Department of Pathophysiology and Transplantation University of Milan Milan Italy

3. University of Witwatersrand and NHLS Johannesburg South Africa

4. Departments of Pediatrics and Pathology University of Michigan Medical School Ann Arbor MI USA

5. University of Manchester Manchester UK

6. World Federation of Hemophilia Montreal QC Canada

7. Genentech, Inc. South San Francisco CA USA

8. University of Washington Seattle WA USA

9. Washington Center for Bleeding Disorders Seattle WA USA

10. Nara Medical University Kashihara Japan

Funder

Roche

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15187

Reference47 articles.

1. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

2. Safety and efficacy of emicizumab and other novel agents in newborns and infants

3. Food and Drug Administration.HEMLIBRA®(emicizumab‐kxwh) injection for subcutaneous use prescribing information. Initial U.S. approval: 2017.2018;https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf. Accessed April 28 2020.

4. European Medicines Agency.HEMLIBRA®solution for injection: emicizumab piIEa. Initial EU approval: 2018.2019.https://www.ema.europa.eu/en/documents/product‐information/hemlibra‐epar‐product‐information_en.pdf. Accessed April 28 2020.

5. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

2. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence;Haemophilia;2024-01-30

3. Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity;Haemophilia;2023-12-06

4. Early stage clinical trials for the treatment of hemophilia A;Expert Opinion on Investigational Drugs;2022-11-02

5. Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction;Frontiers in Medicine;2022-08-05